Genentech Announces FDA Approval of Piasky for Paroxysmal Nocturnal Hemoglobinuria

U.S. FDA drug approval information shows that Piasky, developed by Genentech for the treatment of paroxysmal nocturnal hemoglobinuria, received FDA approval on June 20 local time. Piasky is administered via intravenous or subcutaneous injection. Genentech is a subsidiary of Roche. (Cailian Press)Original Link